Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
Strategic Collaboration: Apollomics Inc. has partnered with LaunXP to develop vebreltinib in combination with an EGFR inhibitor, receiving a $10 million upfront payment and aiming to expand its clinical dataset for treating non-small cell lung cancer (NSCLC).
Financial Overview: As of December 31, 2024, Apollomics reported $9.8 million in cash, a significant reduction in net loss compared to the previous year, and plans to focus resources on vebreltinib for patients with MET amplification, ensuring operational funding through early 2026.
Trade with 70% Backtested Accuracy
Analyst Views on APLMW
No data
About the author
Apollomics Confirms Ongoing Nasdaq Listing After Hearing Cancellation
Nasdaq Compliance: Apollomics Inc. has received confirmation from Nasdaq that it is in compliance with listing requirements, leading to the cancellation of its appeal hearing regarding a previous delisting notification.
Company Overview: Apollomics is a clinical-stage biopharmaceutical company focused on developing oncology therapies, with its lead drug candidate, vebreltinib, currently in Phase 2 trials for treating non-small cell lung cancer and other advanced tumors.
Nasdaq Suspends Trading of Apollomics Inc., Ltd.
Trading Halt Announcement: Nasdaq announced a trading halt for Apollomics Inc., Ltd. on September 17, 2025, at 14:37:17 Eastern Time due to a request for additional information from the company.
Current Share Prices: The last recorded sale price for Apollomics' ordinary shares was $18.4331, while the warrants were priced at $0.0191, with trading remaining halted until the company complies with Nasdaq's information request.
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
Strategic Collaboration: Apollomics Inc. has partnered with LaunXP to develop vebreltinib in combination with an EGFR inhibitor, receiving a $10 million upfront payment and aiming to expand its clinical dataset for treating non-small cell lung cancer (NSCLC).
Financial Overview: As of December 31, 2024, Apollomics reported $9.8 million in cash, a significant reduction in net loss compared to the previous year, and plans to focus resources on vebreltinib for patients with MET amplification, ensuring operational funding through early 2026.
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
Collaboration Announcement: Apollomics has partnered with LaunXP to develop and commercialize vebreltinib, a c-Met inhibitor combined with an EGFR inhibitor for treating non-small cell lung cancer (NSCLC) in Asia, excluding mainland China, Hong Kong, and Macau.
Financial Terms: Apollomics will receive $10 million upfront, potential pre-commercial milestones of up to $50 million, and royalties on net product sales as part of the agreement.
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Trial Results: Apollomics Inc. announced that its Phase 3 trial of uproleselan for relapsed or refractory acute myeloid leukemia did not show a favorable benefit compared to chemotherapy alone, with median overall survival being lower in the uproleselan group (9.3 months) than in the control group (14.3 months).
Future Plans: The company plans to conclude the uproleselan program and submit full trial results for presentation at a future medical conference, while also focusing on its lead oncology program, vebreltinib, which is currently in clinical trials.
Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
Regaining Compliance: Apollomics Inc. has regained compliance with Nasdaq's minimum bid price requirement, confirming that its Class A ordinary shares have maintained a closing bid price of $1.00 or greater for ten consecutive business days.
Company Overview: Apollomics is a clinical-stage biopharmaceutical company focused on developing oncology therapies, including its lead program vebreltinib, a selective c-Met inhibitor currently in Phase 2 trials for non-small cell lung cancer and other advanced tumors.
Apollomics Confirms Ongoing Nasdaq Listing After Hearing Cancellation
Nasdaq Compliance: Apollomics Inc. has received confirmation from Nasdaq that it is in compliance with listing requirements, leading to the cancellation of its appeal hearing regarding a previous delisting notification.
Company Overview: Apollomics is a clinical-stage biopharmaceutical company focused on developing oncology therapies, with its lead drug candidate, vebreltinib, currently in Phase 2 trials for treating non-small cell lung cancer and other advanced tumors.
Nasdaq Suspends Trading of Apollomics Inc., Ltd.
Trading Halt Announcement: Nasdaq announced a trading halt for Apollomics Inc., Ltd. on September 17, 2025, at 14:37:17 Eastern Time due to a request for additional information from the company.
Current Share Prices: The last recorded sale price for Apollomics' ordinary shares was $18.4331, while the warrants were priced at $0.0191, with trading remaining halted until the company complies with Nasdaq's information request.
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
Strategic Collaboration: Apollomics Inc. has partnered with LaunXP to develop vebreltinib in combination with an EGFR inhibitor, receiving a $10 million upfront payment and aiming to expand its clinical dataset for treating non-small cell lung cancer (NSCLC).
Financial Overview: As of December 31, 2024, Apollomics reported $9.8 million in cash, a significant reduction in net loss compared to the previous year, and plans to focus resources on vebreltinib for patients with MET amplification, ensuring operational funding through early 2026.
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
Collaboration Announcement: Apollomics has partnered with LaunXP to develop and commercialize vebreltinib, a c-Met inhibitor combined with an EGFR inhibitor for treating non-small cell lung cancer (NSCLC) in Asia, excluding mainland China, Hong Kong, and Macau.
Financial Terms: Apollomics will receive $10 million upfront, potential pre-commercial milestones of up to $50 million, and royalties on net product sales as part of the agreement.
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Trial Results: Apollomics Inc. announced that its Phase 3 trial of uproleselan for relapsed or refractory acute myeloid leukemia did not show a favorable benefit compared to chemotherapy alone, with median overall survival being lower in the uproleselan group (9.3 months) than in the control group (14.3 months).
Future Plans: The company plans to conclude the uproleselan program and submit full trial results for presentation at a future medical conference, while also focusing on its lead oncology program, vebreltinib, which is currently in clinical trials.
Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
Regaining Compliance: Apollomics Inc. has regained compliance with Nasdaq's minimum bid price requirement, confirming that its Class A ordinary shares have maintained a closing bid price of $1.00 or greater for ten consecutive business days.
Company Overview: Apollomics is a clinical-stage biopharmaceutical company focused on developing oncology therapies, including its lead program vebreltinib, a selective c-Met inhibitor currently in Phase 2 trials for non-small cell lung cancer and other advanced tumors.
